Abstract 188P
Background
A thorough investigation of the tumor cells and immune microenvironment within the lead-edge area is essential for understanding the mechanisms behind the progression of ICC and devising a targeted therapy in the hope of providing clinical benefits for patients.
Methods
Here, we conducted an analysis based on single-cell RNA sequencing (scRNA-seq) and spatial transcriptome (ST) on samples from the tumor core, paired non-tumorous tissue, and the leading-edge area obtained from 9 ICC patients to delineate the properties of cancer cells, immune microenvironment, and the intricate intercellular interactions within. The analysis results were further validated using H&E staining, multiple immunofluorescence staining (IHC), and a large transcriptome dataset.
Results
Tumor cells at the leading-edge area exhibit a heightened capacity for proliferation compared to those in the tumor core, often found in close proximity to the stroma, including endothelial cells and POSTN+ FAP+ fibroblasts. Within this region, CD8+ T cells are characterized by a naive phenotype, displaying low levels of cytotoxicity and exhaustion, a condition that may be linked to the impaired antigen-presenting capabilities of antigen-presenting cells (APCs). MAIT cells, which are the predominant CD8+ T cell subset infiltrating the leading-edge area of ICC, have been observed to recruit SPP1+ macrophages and are co-localized with POSTN+ cancer-associated fibroblasts (CAFs) in the stromal compartment. The presence of SPP1+ macrophages could potentially foster tumor progression through the activation of CD44 in tumor cells, as well as by their proangiogenic effects.
Conclusions
Utilizing scRNA-seq and spatial transcriptome technologies, our research delineates the distinct characteristics of ICC tumor cells within the leading-edge area, revealing how they interact with and influence the surrounding stroma to sculpt the immune microenvironment. These orchestrated interactions within the tumor milieu offer valuable insights and pinpoint potential therapeutic targets for intervention.
Legal entity responsible for the study
Peking University.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
155P - Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1
Presenter: Anne Chiang
Session: Poster Display session
156P - Liver Metastases Correlate with Shortened Survival and Increased Dissociate Response in Patients Treated with T-Cell Engagers.
Presenter: Noé Herbel
Session: Poster Display session
157P - Preliminary results of a multicentric randomized phase I/IIa trial of an immunotherapy targeting dendritic cells (DC), CD40HVac, in patients with HPV16-positive oropharyngeal carcinoma (OPC)
Presenter: Caroline Even
Session: Poster Display session
158P - XCR1+ dendritic cell (DC) role in antitumoral response to anti PD-L1 antibody: Data from the phase Ib/II trial of DC vaccination in small cell lung cancer patients
Presenter: Maria Gonzalez Cao
Session: Poster Display session
159P - Unveiling the impact of DC vaccination on systemic immunity in advanced malignant melanoma: Preliminary results from the ABSIDE study
Presenter: Giada Sabatino
Session: Poster Display session
160P - Oral DNA vaccination targeting personalised neoantigens in immune checkpoint-inhibitor treated solid tumor patients: Interim results
Presenter: Domas Vaitiekus
Session: Poster Display session
161P - Safety of TrimelVax vaccine for patients with advanced melanoma: Clinical results
Presenter: ROBERTO ESTAY
Session: Poster Display session
162P - EO4010 (EO) + nivolumab (N) ± bevacizumab (B) in patients (pts) with microsatellite stable (MSS) metastatic colorectal carcinoma (mCRC)
Presenter: Romain Cohen
Session: Poster Display session
163P - Effect of split intravenous dosing of oncolytic adenovirus TILT-123 on normal tissue versus tumor macrophages and virus bioavailability in patients with advanced solid tumors
Presenter: Elise Jirovec
Session: Poster Display session
164P - Roginolisib (IOA-244), the first highly selective oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3K_), has immuno-modulatory effects associated with clinical benefits in patients with metastatic uveal melanoma
Presenter: Anna Di Giacomo
Session: Poster Display session